Dianthus initiated with an Overweight at Wells Fargo

Wells Fargo analyst Sadia Rahman initiated coverage of Dianthus (DNTH) with an Overweight rating and $135 price target The firm says the company’s claseprubart “stands out” in the complement inhibitor class. The drug has potential labeling and dosing advantages that support $5B-$6B in multi-indication peak sales potential, the analyst tells investors in a research note. Meanwhile, DNTH212 offers “upside optionality” for Dianthus, adds Wells.